Targeting EGFR signalling pathway in triple negative breast cancer
<p>Epidermal growth factor receptor (EGFR) is frequently overexpressed in the majority of triple negative breast cancer patients (TNBC). However, the molecular determinants behind their limited response to EGFR-targeted therapies are poorly understood. Here, both the acute and chronic response...
Autor principal: | |
---|---|
Altres autors: | |
Format: | Thesis |
Idioma: | English |
Publicat: |
2014
|
Matèries: |